Life Science Investing AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention 18 June
Life Science Investing AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes 16 June
